Evercore ISI analyst Elizabeth Anderson CFA has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Elizabeth Anderson CFA has given her Hold rating due to a combination of factors related to Charles River Labs’ current market positioning and future prospects. The company reported better-than-expected fourth-quarter results, which aligns with a realistic 2025 outlook, setting a positive tone despite existing demand constraints. Management is addressing long-term structural issues through cost-cutting measures and share repurchases, showing a commitment to improving financial health.
Despite some confusion regarding the business-to-business metrics during the earnings call, management’s guidance on 2025 DSA revenue seems reasonable, especially in light of recent decisions affecting the supply chain. The current cycle appears to be stabilizing, but further positive demand signals are needed before a more optimistic earnings outlook can be justified. Consequently, the price target has been updated to $175, reflecting these insights.
According to TipRanks, Anderson CFA is an analyst with an average return of -6.3% and a 41.67% success rate. Anderson CFA covers the Healthcare sector, focusing on stocks such as CVS Health, Walgreens Boots Alliance, and Labcorp Holdings.
In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $166.00 price target.